Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
Interim CEO Tal Zaks, M.D., Ph.D., to continue as executive chair
BOSTON, Jan. 27, 2025 /PRNewswire/ -- Averna Therapeutics, Inc. ('Averna"; formerly known as Exsilio Therapeutics, Inc.), a biotechnology company developing genomic medicines that insert therapeutic changes into the genome, today announced the appointment of Thomas M. Barnes, Ph.D., as chief executive officer (CEO) and director. Dr. Barnes brings more than 25 years of biotech industry leadership experience, with a proven track record of advancing innovative therapies, most recently as the CEO of Orna Therapeutics. Dr. Barnes replaces Tal Zaks, M.D., Ph.D., who served as interim CEO and will continue as the executive chairman of Averna's board.
'Tom has an extraordinary talent for transforming groundbreaking science into scalable biotechnology companies focused on developing entirely new ways of treating disease,' said Dr. Zaks. 'His ability to lead the translation of scientific innovation into real-world medicines is unparalleled. We are excited to have Tom at the helm as we develop our RNA/LNP-based genomic medicines.'
Averna is developing RNA/lipid nanoparticle (LNP)-based genomic medicines to insert genes into 'safe harbor' sites in the genome – places where a gene can be inserted safely and without disrupting normal cell function.
'The ability to insert therapeutic genetic material into the genome in a safe and durable way is the last great missing tool from the genetic medicine toolkit, and I have been deeply impressed by the progress the team has made under Tal's leadership,' said Dr. Barnes. 'Averna is now poised to complete that toolkit and deploy it where it will have the greatest impact. I'm proud to work with and expand the talented team at Averna to advance our therapeutic programs and deliver meaningful solutions for patients.'
Dr. Barnes most recently served as CEO of Orna Therapeutics Inc., an RNA/LNP company pioneering the use of circular RNA payloads combined with immune cell LNP delivery. During his tenure, Orna raised more than $450 million and established a major collaboration agreement with Merck, that was then the largest deal for a preclinical company in biotech history. With Orna's acquisition of ReNAgade Therapeutics Inc., he transitioned the CEO role to Amit D. Munshi, CEO of ReNAgade. Dr. Barnes also served as an Entrepreneur Partner at MPM BioImpact. Prior to Orna, as chief scientific officer and a member of the founding team at Intellia Therapeutics Inc., he established the discovery team and led efforts to expand the company's CRISPR platform, helping to raise more than $300 million including through its initial public offering. Earlier in his career Dr. Barnes also co-founded or played a key role in launching several biotech companies, including Eleven Biotherapeutics. Dr. Barnes earned his doctorate from the University of Cambridge and completed research fellowships at Harvard Medical School and McGill University.
Company Changes Name from Exsilio Therapeutics to Averna Therapeutics
In addition to the appointment of the new CEO, the company has changed its name from Exsilio Therapeutics to Averna Therapeutics. Recently, the company was named as one of BioSpace's '25 Promising New Biopharma Companies to Watch in 2025.'
About Averna Therapeutics
Averna Therapeutics is a biotechnology company developing RNA/lipid nanoparticle (LNP)-based genomic medicines to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Averna's proprietary technology is based on a natural system and inserts therapeutic genetic instructions into 'safe harbor' sites in the genome – genomic regions that allow stable gene integration without disrupting normal cell function. Because Averna's medicines are encoded in RNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent. For more information, please visit www.avernatx.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Weyerhaeuser Reports Second Quarter 2025 Results
SEATTLE, July 24, 2025 /PRNewswire/ -- Weyerhaeuser Company (NYSE: WY) today reported its second quarter 2025 financial results. The company's earnings release and associated materials are available on the Investors section of the company's website, In addition, the earnings release has been furnished on a Form 8-K with the U.S. Securities and Exchange Commission and is available at EARNINGS CALL INFORMATIONThe company will hold a live conference call at 7 a.m. Pacific (10 a.m. Eastern) on July 25, 2025, to discuss second quarter results. To access the live webcast and presentation, go to the Investors section on on July 25, 2025. To join the conference call from within North America, dial 877-407-0792 (access code: 13748397) at least 15 minutes prior to the call. Those calling from outside North America should dial 201-689-8263 (access code: 13748397). Replays will be available for two weeks at 844-512-2921 (access code: 13748397) from within North America, and at 412-317-6671 (access code: 13748397) from outside North America. ABOUT WEYERHAEUSERWeyerhaeuser Company, one of the world's largest private owners of timberlands, began operations in 1900 and today owns or controls approximately 10.4 million acres of timberlands in the U.S., as well as additional public timberlands managed under long-term licenses in Canada. Weyerhaeuser has been a global leader in sustainability for more than a century and manages 100 percent of its timberlands on a fully sustainable basis in compliance with internationally recognized sustainable forestry standards. Weyerhaeuser is also one of the largest manufacturers of wood products in North America and operates additional business lines around product distribution, climate solutions, real estate, energy and natural resources, among others. In 2024, the company generated $7.1 billion in net sales and employed approximately 9,400 people who serve customers worldwide. Operated as a real estate investment trust, Weyerhaeuser's common stock trades on the New York Stock Exchange under the symbol WY. Learn more at For more information contact:Analysts – Andy Taylor, 206-539-3907Media – Nancy Thompson, 919-861-0342 View original content to download multimedia: SOURCE Weyerhaeuser
Los Angeles Times
10 minutes ago
- Los Angeles Times
CRISPR and Cancer: How Gene Editing Is Revolutionizing Oncology
Every so often, a tool comes along that feels like science fiction. CRISPR is one of them. It's a pair of molecular scissors that we can program to find one specific spot in three billion letters of DNA and make a cut [2]. Incredible. The hype machine went into overdrive. We were going to edit out diseases. Cure cancer. The end. Here's the problem with that fantasy. Cancer isn't a clean typo. It's a riot. It's a chaotic, messy, ever-changing system that thrives on mistakes. It rewrites its own rulebook as it goes. So you have this exquisitely precise scalpel, and you're trying to use it in the middle of a cellular brawl [7]. It's a mismatch. A big one. This isn't me being cynical. It's just recognizing where the real work is. And right now, the most revolutionary thing CRISPR is doing for cancer has nothing to do with curing patients directly. It's happening in the lab [1]. For years, if we wanted to know what a specific gene did, we had to go through a long, painful process to shut it down. Now? A researcher can just use CRISPR to snip that gene out of a cancer cell in a petri dish and see what happens [4]. Does the cell die? Stop growing? Suddenly become vulnerable to an old drug? We can get answers in weeks, not years. We're building a proper instruction manual for our enemy, and we're doing it at a shocking speed [5]. That's the real revolution so far. It's a research tool. And it's the best one we've ever had. So if we can't just march into the body and 'edit' the tumor away, what's the next best thing? You take the fight somewhere else. Somewhere you can control. That's the whole idea behind CAR-T cell therapy. We take a patient's own immune cells—their T-cells—out of their body and into the lab. We engineer them to recognize cancer. Then we put them back. It can work miracles. It can also fizzle out. The T-cells get tired. The cancer learns to hide. This is where CRISPR gets its first real clinical shot. In the lab, before we put those T-cells back, we can give them a CRISPR tune-up. A few quick snips. We can edit out the gene that tells a T-cell to stand down, making it relentless at it's goal. We can snip out its natural receptors so it doesn't get confused and attack the wrong thing [3]. Better weapons. Stronger armor. A clearer target [10]. We're not fixing the patient. We're upgrading their soldiers in the workshop before sending them to the front lines. This is where the action is right now, especially for nasty, hard-to-treat cancers, like in gynecological oncology or tumors that have stopped responding to anything else [6] [7]. It's practical. It's contained. And it's already happening. But the sci-fi dream of injecting a cure dies hard. Why can't we just do that? It comes down to boring, practical problems. The kinds of problems that kill big ideas. Delivery and safety [3] [9]. First, how do you get the CRISPR machinery into every last cancer cell, deep inside a person's body, without also hitting a bunch of healthy cells by mistake? Our delivery systems just aren't that good yet. It's like trying to mail a million letters and making sure every single one gets to the right house during an active hurricane. Then there's the 'oops' factor. Off-target effects. What if the scissors cut the wrong gene [8]? In the best case, nothing happens. In the worst case, you create a whole new problem. You could, in theory, cause a new cancer while trying to cure the old one. The risk is small. It's getting smaller every year. But it's not zero. And when you're talking about rewriting someone's permanent code, the stakes are as high as they get. So, no. This isn't a magic wand. The revolution is a slow, grinding one. It's happening at the bench, letting us understand the disease. It's happening in the cell processing lab, letting us build better therapies. The idea of a simple cure-in-a-needle remains a distant hope. [1] Wang, S. W., Gao, C., Zheng, Y. M., Yi, L., Lu, J. C., Huang, X. Y., Cai, J. B., Zhang, P. F., Cui, Y. H., & Ke, A. W. (2022). Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Molecular cancer, 21(1), 57. [2] Garg, P., Singhal, G., Pareek, S., Kulkarni, P., Horne, D., Nath, A., Salgia, R., & Singhal, S. S. (2025). Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: A comprehensive overview. Biochimica et biophysica acta. Reviews on cancer, 1880(1), 189233. [3] Shuvalov, O., Petukhov, A., Daks, A., Fedorova, O., Ermakov, A., Melino, G., & Barlev, N. A. (2015). Current genome editing tools in gene therapy: new approaches to treat cancer. Current gene therapy, 15(5), 511–529. [4] Zhao, Z., Li, C., Tong, F., Deng, J., Huang, G., & Sang, Y. (2021). Review of applications of CRISPR-Cas9 gene-editing technology in cancer research. Biological procedures online, 23(1), 14. [5] Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024). Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Molecular cancer, 23(1), 9. [6] Kumar N. (2025). Genome Editing in Gynecological Oncology: The Emerging Role of CRISPR/Cas9 in Precision Cancer Therapy. Therapeutic innovation & regulatory science, 10.1007/s43441-025-00807-w. Advance online publication. [7] Mishra, G., Srivastava, K., Rais, J., Dixit, M., Kumari Singh, V., & Chandra Mishra, L. (2024). CRISPR-Cas9: A Potent Gene-editing Tool for the Treatment of Cancer. Current molecular medicine, 24(2), 191–204. [8] Imyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V. (2021). Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Critical reviews in oncology/hematology, 157, 103194. [9] Uddin, F., Rudin, C. M., & Sen, T. (2020). CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future. Frontiers in oncology, 10, 1387. [10] Murty, T., & Mackall, C. L. (2021). Gene editing to enhance the efficacy of cancer cell therapies. Molecular therapy : the journal of the American Society of Gene Therapy, 29(11), 3153–3162.
Yahoo
32 minutes ago
- Yahoo
The Hanover Launches Workers' Comp Advantage to Simplify, Expedite New Business Process for Small Commercial Clients
WORCESTER, Mass., July 24, 2025 /PRNewswire/ -- The Hanover Insurance Group, Inc. (NYSE: THG) announced today the launch of Workers' Comp Advantage, a new addition to its business submission platform, designed to simplify and accelerate the quoting and binding process for small business clients. The Agency Place (TAP) Sales, The Hanover's industry-leading online quoting and issuance platform for agents, offers a suite of coverages including business owner's policy, marine, and professional and management liability products. The integration of Workers' Comp Advantage into the platform marks another step in the company's ongoing investment in digital innovation for small commercial insurance. "This is an important advancement in our digital journey, one that helps enhance the experience for our agents," said Charles F. Hamann, president and chief underwriting officer, small commercial at The Hanover. "Workers' Comp Advantage enables our agents to offer leading workers' compensation solutions to their customers, streamlining the quoting process and helping them deliver insurance solutions even faster and more efficiently." A bindable Workers' Comp Advantage quote can be delivered in less than two minutes, with up to 90% straight-through processing across many target classes. The platform offers: An enhanced experience: A sleek, intuitive interface that works seamlessly with the company's business owner's policy for a more cohesive quoting experience Simplified entry: Prefilled fields and the ability to quote with just seven pieces of information Pricing flexibility: Adjustable pricing and access to state-specific safety credit programs based on clients' risk management practices Faster policy delivery: Instantly generates customized quote proposals and delivers policies electronically to agents, enabling real-time delivery to customers In addition, agents can seamlessly offer their clients access to other value-added services from The Hanover, such as Nurse Triage 24, providing immediate injury response, and Hanover EZ Pay, a pay-as-you-go billing option for workers' compensation. "With Workers' Comp Advantage, we're giving our independent agent partners the speed and flexibility they need to quote and bind more efficiently, helping them better serve their clients," said Erin A. Fenlon, vice president, chief operations officer, small commercial at The Hanover. Workers' Comp Advantage is currently available in Idaho, Illinois, Indiana, Maryland, New Hampshire, Utah, Vermont and Virginia. Additional states will be added throughout the year, including South Carolina and Tennessee in August. For more information about Workers' Comp Advantage and The Hanover's small commercial insurance solutions, please visit About The Hanover The Hanover Insurance Group, Inc. is the holding company for several property and casualty insurance companies, which together constitute one of the largest insurance businesses in the United States. The company provides exceptional insurance solutions through a select group of independent agents and brokers. Together with its agent partners, The Hanover offers standard and specialized insurance protection for small and mid-sized businesses, as well as for homes, automobiles, and other personal items. For more information, please visit Media contacts:Abby C. Ursoleo Emily P. Trevallion aursoleo@ etrevallion@ 508-855-3549 508-855-3263 All products are underwritten by The Hanover Insurance Company or one of its insurance company subsidiaries or affiliates ("The Hanover"). Coverage may not be available in all jurisdictions and is subject to the company underwriting guidelines and the issued policy. This material is provided for informational purposes only and does not provide any coverage. View original content to download multimedia: SOURCE The Hanover Insurance Group, Inc. Sign in to access your portfolio
